Chemicals

Amyris to Acquire Sweet-Protein Developer Oobli

The biomanufacturing company adds Oobli's fermentation-derived sweet proteins to its strain engineering and production scale, with the deal expected to close within weeks.

Erik LindqvistNovember 16, 20265 min read1 views
Polished stainless-steel fermentation vessels beside a laboratory bench with dishes of white protein powder, berries and a dissolving sugar-cube form.

Amyris, Inc. (Emeryville, Calif.), a vertically integrated biomanufacturing company, announced that it will acquire Oobli Inc. (Davis, Calif.), whose fermentation-based sweet protein ingredients are used by food and beverage brands to reduce sugar without sacrificing taste.

The company said the transaction combines its scientific capabilities and manufacturing depth with Oobli's protein fermentation expertise. It follows a capacity expansion completed earlier this year at Amyris' advanced fermentation facility in Barra Bonita, Brazil, and is described by the company as a strategic commercial and technology expansion that accelerates its footprint in protein- and peptide-based solutions across end markets.

Complementary technology platforms

Chief executive officer Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris' own. Oobli, she said, is positioned to change how sweetness reaches the market, and Amyris intends to apply its commercial scale and resources to speed that effort. Combining Oobli's protein expertise with Amyris' strain engineering, manufacturing scale and commercial capabilities could broaden the combined company's reach in food and beverage, personal care, flavor and fragrances, agriculture and beyond, she added.

Oobli's commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform. The company spent the past decade refining a fermentation process for producing sweet proteins found naturally in rare fruits and berries grown near the equator. According to Oobli, the ingredients are the first of their kind in the sugar reduction category: they are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes.

The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin. The ingredients hold FDA GRAS status and are FEMA GRAS-affirmed for use as a natural flavor. Oobli said growing consumer awareness of metabolic health and sugar reduction gives brands a tool applicable across sports nutrition, dairy, beverages, chocolate, bakery and confectionery.

Closing expected in coming weeks

Oobli chief executive officer Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health or the environment. Joining with Amyris, she said, gives Oobli the scale and resources to pursue its ambition of making sweet proteins a standard in sweetness solutions.

Fortmann said biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform does so by addressing sweet taste, sugar reduction and clean label at the same time. The acquisition is expected to close in the coming weeks; Amyris said all existing Oobli customer commitments and brand partnerships will be honored without interruption.